<DOC>
	<DOC>NCT00294541</DOC>
	<brief_summary>This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD) (e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb+-thalassemia subjects). All subjects who have successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator and appropriate consent by subject is given, enroll in the ICA-17043-12 study (Study 12). Only patients who participated in ICA-17043-10 are eligible for this open label study</brief_summary>
	<brief_title>A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Successfully completed Study ICA1704310 Discontinued Study 10 or 12 following the DMC recommendations because he/she was not on HU, and has since been on a stable dose of HU for at least 3 months prior to Day 1 Male, or female not capable of becoming pregnant or using appropriate birth control Has willingly given written informed consent to participate in this study The subject, if female, has a positive urine pregnancy test on Day 1 (before entering study) The subject is presently unsuitable for participation in this longterm study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
</DOC>